AbbVie (ABBV) | Stock Overview & Key Data
AbbVie Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $244.81 on October 1, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
AbbVie
ABBV
|
351.47B Mega-cap | 1.07% | 3.48% | -8.05% | -4.00% | -6.07% | 16.98% | 59.07% | 93.77% | 234.95% | 559.76% | 559.76% |
|
Eli Lilly and
LLY
|
821.31B Mega-cap | -0.01% | 9.99% | 4.58% | 1.77% | -1.46% | 49.80% | 149.81% | 446.98% | 1,370.98% | 2,882.46% | 2,023.77% |
| 555.84B Mega-cap | -3.15% | -0.57% | -10.32% | 8.52% | 7.51% | 45.18% | 43.55% | 35.77% | 96.35% | 240.94% | 270.97% | |
|
Merck & Co
MRK
|
283.10B Mega-cap | -3.39% | 2.25% | -4.74% | 14.48% | 8.65% | 54.50% | 5.51% | 60.19% | 119.65% | 247.54% | 266.76% |
|
Medicus Pharma
MDPLD
|
N/A | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | N/A | N/A | N/A | N/A | N/A | N/A |
|
Amgen
AMGN
|
187.93B Large-cap | -2.29% | 1.36% | -14.89% | -2.98% | 0.19% | 16.87% | 54.44% | 42.20% | 111.56% | 473.85% | 386.83% |
Ownership & Short Interest
Calculate Your AbbVie Investment Returns
Long-Term Investment Performance Analysis
AbbVie stock price in May 2016 was $65.00, A $1,000.00 lump sum investment in AbbVie made 10 years ago would be worth approximately $3,340.46 today, representing a outstanding return of 234.05%. This translates to an annualized return (CAGR) of 12.81%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ABBV's 52-week high and low?
- In the last 52 weeks, AbbVie reached a high of $244.81 (on October 1, 2025) and a low of $181.73 (on June 27, 2025).
- What is the market cap and P/E ratio for ABBV?
- Curious about AbbVie's size and valuation? Its market capitalization stands at 351.47B. When it comes to valuation, the P/E ratio (trailing twelve months) is 83.46, and the forward P/E (looking ahead) is 12.30.
- Does ABBV pay dividends? If so, what's the yield?
- Yes, AbbVie is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.10%, and the company has paid an average of $6.31 per share annually over the past 3 years.
- Who are AbbVie's main competitors or similar companies to consider before investing?
When looking at AbbVie, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY821.31B Healthcare Drug Manufacturers - General 49.80% 149.81% Johnson & Johnson
JNJ555.84B Healthcare Drug Manufacturers - General 45.18% 43.55% Merck & Co
MRK283.10B Healthcare Drug Manufacturers - General 54.50% 5.51% Medicus Pharma
MDPLDN/A Healthcare Drug Manufacturers - General N/A N/A Amgen
AMGN187.93B Healthcare Drug Manufacturers - General 16.87% 54.44% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for AbbVie Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of AbbVie's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 6,225.00%, the Debt to Equity ratio from the most recent quarter is -21.19, and its Gross Profit Margin stands at 72.61%.
- What is the recent revenue and earnings growth for ABBV?
- Looking at AbbVie's growth, its revenue over the trailing twelve months (TTM) was $61B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.00%, and quarterly earnings saw a YoY growth of 10.04%.
- How much of ABBV stock is held by insiders and institutions?
- Wondering who owns AbbVie stock? Company insiders (like executives and directors) hold about 0.12% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 76.78%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.